louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06853275: The Influence of Movement Velocity Biofeedback on Muscle Activation and Self Perception in Older Adults With Sarcopenia
Official title: The Influence of Movement Velocity Biofeedback on Muscle Activation and Self Perception in Older Adults With Sarcopenia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Sarcopenia
Sarcopenia in Elderly
Age-associated Muscle Loss
Keywords: Geriatrics
Neuromuscular
Rehabilitation
Sarcopenia
Velocity-based training
Lead sponsor: Creighton University
Sponsor class: OTHER
Collaborators: name: Foundation for Physical Therapy Research
First posted: 2025-02-28
Enrollment: 60
Sex: ALL
Minimum age (years): 60
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The overall objective for this clinical trial is to provide evidence for internal and external cueing for physical therapists and other rehabilitation clinicians to optimize resistance training within rehabilitation for older adults. The main questions it aims to answer are:

* What is the impact of external focus (providing velocity of movement for each repetition) compared to internal focus (i.e., no cues, control group) on physical percent velocity loss and neuromuscular activation in older adults with sarcopenia?
* Does internal and external focus influence motivation and perceptual workload following resistance training in older adults with sarcopenia?

Researchers will compare external focus to internal focus to see if external focus impacts percent velocity loss, motivation, and perceived workload.

Participants will:

* Visit the lab once per week for 3 weeks
* Perform exercise testing using a leg press
* Answer questionnaires regarding perceived workload and motivation before and after exercise


Eligibility criteria: Inclusion Criteria:

* Community-dwelling older adults 60-95 years of age
* Physically independent
* Free of severe mental impairment
* Score 4 or greater on the SARC-F sarcopenia questionnaire

Exclusion Criteria:

* Participated in a structured resistance training program in the last 12 months
* Had a lower extremity injury or surgical intervention within the past 6 months
* Have neuromuscular (i.e., Parkinson's Disease, Multiple Sclerosis), circulatory, or edema pathology

Primary outcomes:
measure: Percent Velocity Loss
timeFrame: Week 1 and Week 2 Timepoints
measure: Muscle Activation
timeFrame: Baseline, Week 1, and Week 2 Timepoints
measure: Motivation
timeFrame: Week 1 and Week 2 Timepoints
measure: Perceived Workload
timeFrame: Week 1 and Week 2 Timepoints
Secondary outcomes:
Other outcomes:
Locations:
city: Omaha
country: United States
facility: Creighton University
state: Nebraska
Study officials:
References:
Clinical trial NCT06971575: Cervical Radiculopathy Imaging Using MRN With Electrodiagnostic Correlation
Official title: Cervical Radiculopathy Imaging Using MR Neurography With Electrodiagnostic Correlation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cervical Radiculopathy
Lead sponsor: Hospital for Special Surgery, New York
Sponsor class: OTHER
First posted: 2025-05-14
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with acute or subacute unilateral cervical radiculopathy and signs of clinical weakness

Brief summary: This project will study patients with cervical radiculopathy. We will evaluate the combined diagnostic and prognostic value of magnetic resonance neurography (MRN), electrodiagnostic (EDX) studies, and historical and physical clinical elements. Specifically, this project will explore whether these data individually or in combination correlate with response to procedural and non-procedural treatment.


Eligibility criteria: Inclusion Criteria:

* Patients presenting with symptoms compatible with acute or subacute unilateral (one-sided) cervical radiculopathy and signs of clinical weakness
* 18-60 years old at the time of evaluation
* Symptom onset of 2 to 12 weeks leading up to baseline visit
* Diagnosis of unilateral cervical radiculopathy, with or without spinal cord compression, based on signs and symptoms, physical exam and supported by MRI findings of radiculopathy (as evidenced by foraminal stenosis/narrowing) based on standard-of-care cervical spine MRI
* Patients who have undergone or have planned electrodiagnostic testing at HSS prior to surgery

Exclusion Criteria:

* Prior cervical surgery or instrumentation
* Those who have had a prior episode of cervical radiculopathy
* History of peripheral neuropathy or another acute or chronic neurodegenerative condition
* History of stroke, cerebellar disease, or central nervous system disease
* Contraindications to undergoing a standard MRI examination (e.g., pregnancy)
* Patients presenting with bilateral cervical radiculopathy

Primary outcomes:
measure: Presence of abnormalities on nerve (MRN) imaging
timeFrame: Baseline
measure: Relationship between abnormalities on imaging and electrodiagnostic assessment
timeFrame: Baseline
Secondary outcomes:
measure: Numeric rating scale (NRS) pain
timeFrame: Baseline, 3 months, 6 months, 12 months
measure: Neck Disability Index (NDI)
timeFrame: Baseline, 3 months, 6 months, 12 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Hospital for Special Surgery
state: New York
Study officials:
References:
Clinical trial NCT03657875: Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network (HEKATE)
Official title: Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD)
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2018-09-05
Enrollment: 53940
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients in Russia 18 years and older whose blood samples were analysed in the independent laboratory INVITRO for serum potassium level (K), from 01.01.2015 till 31.12.2016.

From the main dataset with serum potassium level, subgroups will be selected with available serum sodium (Na), creatinine (for calculation of eGFR with CKD-EPI formula), urine albumin, HbA1C, and NT-proBNP or BNP.

Brief summary: This is a cross-sectional retrospective study of laboratory records of patients who take electrolytes blood tests containing the data of the serum potassium level. This study is an observational one, and there is no intervention into routine clinical practice either in terms of therapy, or special examinations.


Eligibility criteria: Inclusion Criteria:

* Males and females tested in the Russian centres of INVITRO laboratory from 01.01.2015 till 31.12.2016;
* 18 years and older;
* Available electrolytes blood test containing of the serum potassium level of the unique patient fits for interpretation.

Exclusion Criteria:

* Blood test cannot be interpreted due to various reasons.
* Blood samples with sing of hemolysis

Primary outcomes:
measure: the proportion of the individuals with the serum potassium level higher than 5.0, 5.5, and 6.0 mmol/L
timeFrame: One day
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: Invitro
Study officials:
References:
Clinical trial NCT06755775: PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Official title: PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Diffuse Large B-Cell Lymphoma
Keywords: PET/CT
Granzyme B
immunotherapy
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2025-01-01
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chinese patient with pathologically confirmed diffuse large B-cell lymphoma

Brief summary: This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.

Detailed description: The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy (CAR-T, Glofitamab or iR2 ).

Eligibility criteria: Inclusion Criteria:

1. Pathologic diagnosis of DLBCL
2. Patient's general condition is good and survival is expected to be greater than six months
3. Signed and dated informed consent form

Exclusion Criteria:

1. Combined with other malignant tumors
2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
3. Pregnant women and women at risk of pregnancy, breastfeeding women
4. poor compliant

Primary outcomes:
measure: The value of PET imaging targeting granzyme B in predicting the efficacy of immunotherapy for diffuse large B-cell lymphoma
timeFrame: Baseline and 2 weeks after treatment
measure: Standardized uptake value (SUV)
timeFrame: Baseline and 2 weeks after treatment
Secondary outcomes:
measure: Progress free suivival
timeFrame: 3 years
measure: Overall survival
timeFrame: 3 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School
Study officials:
References:
Clinical trial NCT02018575: Metabolic Availability of Lysine From White Maize
Official title: Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From White Maize Protein, in Young Adult Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Adults
Keywords: lysine
bioavailability
amino acids
corn
Lead sponsor: The Hospital for Sick Children
Sponsor class: OTHER
First posted: 2013-12-23
Enrollment: 7
Sex: MALE
Minimum age (years): 20
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Our objective is to determine the metabolic availability of Lysine in white maize using the indicator amino acid oxidation (IAAO) technique in adult men.

Detailed description: Our objective is to determine the metabolic availability of Lysine in white maize. 7 young, healthy, male adults will receive graded levels (29, 37,46 and 54%) of lysine requirement of 35 mg/kg/d as a crystalline AA mixture and a porridge of white cornmeal protein respectively.

Eligibility criteria: Inclusion Criteria:

* Healthy Adult males (20-49 years old)

Exclusion Criteria:

* A history of recent weight loss or illness
* Use of any medication at the time of entry into the study

Primary outcomes:
measure: Metabolic Availability of Lysine
timeFrame: Baseline
Secondary outcomes:
measure: Metabolic Availability of Lysine
timeFrame: 15 mins after intake of the fourth hourly meal (before tracer infusion)
Other outcomes:
measure: Metabolic availability of Lysine
timeFrame: 30 mins after intake of the fourth hourly meal (before tracer infusion)
measure: Metabolic Availability of Lysine
timeFrame: 45 mins after intake of the fourth hourly meal (before tracer infusion)
measure: Metabolic Availability of Lysine
timeFrame: Post Tracer Infusion (between 150 and 240 min of tracer infusion)
Locations:
city: Toronto
country: Canada
facility: The Hospital for Sick Children
state: Ontario
Study officials:
affiliation: The Hospital for Sick Children, Toronto, Canada
name: Paul B Pencharz, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04921475: Renal Regional Oxygen Saturation During Transcatheter Aortic Valve Implantation
Official title: Association of Renal Regional Oxygen Saturation and Postprocedural Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Implantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Injury, Acute
Transcatheter Aortic Valve Implantation
Keywords: renal regional oxygen saturation
acute kidney injury
transcatheter aortic valve implantation
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2021-06-10
Enrollment: 65
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients (age \>= 20 years) undergoing transfemoral transcatheter aortic valve implantation are eligible for this observational study.

Brief summary: This prospective observational study evaluates the association of peri-procedural changes in renal regional oxygen saturation and post-procedural acute kidney injury in patients undergoing transcatheter aortic valve implantation.

Detailed description: This prospective observational cohort study evaluated the association of renal regional oxygen saturation, measured during transcatheter aortic valve implantation, and post-procedural acute kidney injury. Renal regional oxygen saturation is measured using near-infrared spectroscopy on the skin surface over the kidneys.

Eligibility criteria: Inclusion Criteria:

* Adult patients (\>= 20 years old) undergoing transcatheter (transfemoral) aortic valve implantation

Exclusion Criteria:

* Emergent procedure
* Pre-procedural severe renal impairment (eGFR \< 30 mL/min/1.73 m2)
* Pre-procedural hemodialysis
* Distance from skin to renal capsule \> 4 cm
* Pre-procedural mechanical ventilation
* Refuse to participate

Primary outcomes:
measure: acute kidney injury
timeFrame: during 7 days post-TAVI
Secondary outcomes:
measure: composite complication
timeFrame: during 7 days post-TAVI or until discharge
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Youn Joung Cho, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03484975: Novasight Hybrid Intravascular Ultrasound and Optical Coherence Tomography System (IVUS OCT)
Official title: Novasight Hybrid Intravascular Ultrasound and Optical Coherence Tomography System (IVUS OCT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stable Angina
Acute Coronary Syndrome
Lead sponsor: Conavi
Sponsor class: INDUSTRY
First posted: 2018-04-02
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Collection of coronary images with a hybrid IVUS OCT system.

Detailed description: A prospective observational imaging study in patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.

Eligibility criteria: Inclusion Criteria:

1. Patient is at least 18 years old.
2. Patients arriving for coronary angiography or possible PCI with stable angina or acute coronary syndrome (including unstable angina, NSTEMI or STEMI).
3. Patients with STEMI may be undergoing subsequent staged PCI to additional coronary stenoses after the index STEMI event has been successful treated with primary PCI.
4. Vascular access of at least 6F.
5. Patient provides informed, written consent for participation in the study.
6. A target lesion is present in a suitable artery for intravascular imaging.

Exclusion Criteria:

1. Angiographic evidence of severe calcification
2. Marked tortuosity that precludes imaging of a target coronary artery.
3. GFR (Glomerular filtration rate) \<35 mL/min.
4. Patients in cardiogenic shock.
5. Women of child bearing potential, in whom pregnancy cannot be excluded.
6. Patients of age \< 18 years old.
7. Patients with an allergy to contrast.
8. Patients unable to grant informed, written consent for participation in the study.

Primary outcomes:
measure: Collection of the first human coronary images with the hybrid IVUS OCT technology
timeFrame: Clinical Report Forms (capturing image analysis) will be completed for each case no later then 72 hours after the procedure.
Secondary outcomes:
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: Hamilton General Hospital
state: Ontario
Study officials:
affiliation: Hamilton General Hospital
name: Tej Sheth, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04164875: Fever During Labour
Official title: Fever During Labour
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fever; Due to Heat
Infection
Keywords: fever
epidural
birth
labour
Lead sponsor: Herlev Hospital
Sponsor class: OTHER
First posted: 2019-11-15
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant women.

Brief summary: Pilot study to assess fever during labour.

Detailed description: 200 parturients will be monitored for fever during labour using rectal thermometer.

Repeated measurements 1/hr during the first 6 hours will allow us to find patients developing fever.

Fever = rectal temp \>38 Celsius twice within 60 min or 39 degrees Celsius measured once .

After birth, blood samples are assessed for infection. Use of Antibiotics and other medication is Recorded. Subgroup analyses based on suspected causes of fever during birth.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years, planned vaginal birth, able to give consent

Exclusion Criteria:

* do not speak Danish or English, unable to cooperate to rectal temperature measurements,

Primary outcomes:
measure: Fever
timeFrame: during labour
Secondary outcomes:
measure: CRP
timeFrame: 24 hours
measure: Leucocytosis
timeFrame: 24 hours
measure: bacterial growth blood
timeFrame: 1 week
measure: bacterial growth placenta blood
timeFrame: 1 week
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Department of Anaesthesiology
Study officials:
affiliation: Herlev Hospital, Afdeling for Bedøvelse og Operation
name: Kim Wildgaard, MD phd
role: STUDY_CHAIR
affiliation: Herlev Hospital, Dept. of Obstetriscs
name: Lærke Vinberg Rasmussen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01592175: Magnetoencephalography (MEG), Attention and Conscience
Official title: Spatio-temporal Dynamic of the Relationship Between Spatial Attention and Visual Awareness
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Change in Sustained Attention
Awareness
Reaction Time
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2012-05-07
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young adults living in Paris or around fulfilling the eligibility criteria

Brief summary: The tight relationship between attention and conscious perception makes them difficult to study in isolation and has led many scientists to closely link these two processes. However, while some authors argue that conscious perception cannot occurs without attention, magnetoencephalography (MEG) and fMRI studies had shown that attention and consciousness are two distinct brain processes.

If endogenously triggered attention and consciousness are dissociated, it has been proposed that orienting of exogenous attention is a necessary, though not sufficient, antecedent of conscious perception.

In the present study we used MEG to explore the neural correlates of exogenous attention and consciousness during visual processing.


Eligibility criteria: Inclusion Criteria:

* Subjects aged between 18 and 40 who have signed informed consent for participation to the study and are affiliated to a social security regimen
* right-handler, without auditory or visual deficit

Exclusion Criteria:

* history of neurological or psychiatic disease
* medication
* sensory disorders

Primary outcomes:
measure: Brain activity during visuo-spatial attention tasks
timeFrame: Three years
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: CRICM
Study officials:
References:
Clinical trial NCT00005875: Nitrocamptothecin in Treating Patients With Metastatic Melanoma
Official title: Phase II Evaluation of RFS 2000 (9-Nitro-Camptothecin, 9NC) in Metastatic Melanoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Melanoma (Skin)
Keywords: stage IV melanoma
recurrent melanoma
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
First posted: 2004-04-13
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have metastatic melanoma.

Detailed description: OBJECTIVES: I. Assess the efficacy and toxicity of nitrocamptothecin in patients with metastatic melanoma.

OUTLINE: Patients are stratified according to disease (choroidal vs nonchoroidal). Patients receive oral nitrocamptothecin daily on days 1-5. Treatment continues weekly for at least 8 weeks (2 courses) in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 28-74 patients (14-37 per stratum) will be accrued for this study.

Eligibility criteria: DISEASE CHARACTERISTICS: Histologically or cytologically confirmed metastatic melanoma Choroidal (no prior chemotherapy required) OR Nonchoroidal No more than 3 chemotherapy regimens Bidimensionally measurable disease No symptomatic uncontrolled CNS involvement including extensive brain metastases, spinal cord compression, or meningeal carcinomatosis Not eligible for treatment protocol of higher priority

PATIENT CHARACTERISTICS: Age: Over 16 Performance status: Zubrod 0-2 Life expectancy: Greater than 8 weeks Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Transaminase no greater than 3 times ULN Renal: Creatinine no greater than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 1 year after study No serious concurrent illness

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy and recovered Surgery: Not specified

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Dublin
country: United States
facility: SuperGen, Incorporated
state: California
Study officials:
affiliation: Astex Pharmaceuticals, Inc.
name: Show-Li Sun, MD
role: STUDY_CHAIR
References: